CRA's RADAR Insights: Factors impacting GKV rebates for orphan drugs in Germany - Part 1
Germany’s AMNOG introduced in 2011 follows health technology assessments (HTAs) with reimbursement price negotiations and some exceptions for orphan drugs...
Andras Ruppert
Vice President
Andras Ruppert is a vice president in the Life Sciences Practice at CRA. He has more than 20 years of experience working in the pharmaceutical, biotech, and medical device industries globally, solving strategic issues.
Mr. Ruppert is an expert in European healthcare systems, including their funding, evaluation, and reimbursement processes. He also helps life sciences companies to adjust internal structures and processes to the changing environment.
Prior to his role at CRA, Mr. Ruppert held senior positions at QuintilesIMS, now doing business as IQVIA, most recently as a vice president and head of their global consulting business out of Europe. He is fluent in English, German, and Norwegian.
Credentials
Get In Touch
Andras Ruppert